Drug Interactions between nalbuphine and tramadol
This report displays the potential drug interactions for the following 2 drugs:
- nalbuphine
- tramadol
Interactions between your drugs
nalbuphine traMADol
Applies to: nalbuphine and tramadol
GENERALLY AVOID: Concomitant use of tramadol increases the seizure risk in patients taking other opioids. These agents are often individually epileptogenic and may have additive effects on seizure threshold during coadministration. CNS- and respiratory-depressant effects may also be additive. In patients who have been previously dependent on or chronically using opioids, tramadol can also reinitiate physical dependence or precipitate withdrawal symptoms.
GENERALLY AVOID: Mixed opioid agonist-antagonist analgesics such as buprenorphine, butorphanol, nalbuphine, and pentazocine may theoretically decrease the analgesic effects of tramadol or cause withdrawal symptoms in patients who have been taking tramadol.
MANAGEMENT: Concomitant use of tramadol and other opioids, including mixed agonist/antagonist analgesics, should be avoided in general. Tramadol should not be used in opioid-dependent patients, and use in patients who are chronically on opioids is also not recommended. Tramadol is contraindicated in patients with acute opioid intoxication. Tramadol dosage should be reduced if it must be used in patients receiving opioids. Patients should be monitored for development of seizures and CNS and respiratory depression.
References (1)
- (2001) "Product Information. Ultram (tramadol)." McNeil Pharmaceutical
Drug and food/lifestyle interactions
nalbuphine food/lifestyle
Applies to: nalbuphine
GENERALLY AVOID: Alcohol may potentiate the central nervous system (CNS) depressant effects of opioid analgesics. Concomitant use may result in additive CNS depression and impairment of judgment, thinking, and psychomotor skills. In more severe cases, hypotension, respiratory depression, profound sedation, coma, or even death may occur. In addition, alcohol may affect opioid release from sustained-release formulations.
MANAGEMENT: Patients should not consume alcoholic beverages or use drug products that contain alcohol during treatment with opioid analgesics. Any history of alcohol or illicit drug use should be considered when prescribing an opioid analgesic, and therapy initiated at a lower dosage if necessary. Patients should be closely monitored for signs and symptoms of sedation, respiratory depression, and hypotension.
References (9)
- (2024) "Product Information. Oxymorphone Hydrochloride (oxyMORphone)." Aurolife Pharma LLC
- (2024) "Product Information. Levorphanol Tartrate (levorphanol)." Virtus Pharmaceuticals LLC
- (2025) "Product Information. Nalbuphine Hydrochloride (nalbuphine)." Hospira Inc
- (2024) "Product Information. Remifentanil Hydrochloride (remifentanil)." Fresenius Kabi USA, LLC
- (2022) "Product Information. Remifentanil (remifentanil)." Wockhardt UK Ltd
- (2024) "Product Information. Cyclizine-Dipipanone (cyclizine-dipipanone)." Advanz Pharma
- Cherrier MM, Shen DD, Shireman L, et al. (2021) "Elevated customary alcohol consumption attenuates opioid effects." Pharmacol Biochem Behav, 4, p. 1-27
- (2024) "Product Information. Oxymorphone Hydrochloride ER (oxyMORphone)." Amneal Pharmaceuticals LLC
- (2025) "Product Information. Dihydrocodeine (dihydrocodeine)." Ennogen Healthcare International Ltd
traMADol food/lifestyle
Applies to: tramadol
GENERALLY AVOID: Alcohol may potentiate the central nervous system (CNS) depressant effects of opioid analgesics. Concomitant use may result in additive CNS depression and impairment of judgment, thinking, and psychomotor skills. In more severe cases, hypotension, respiratory depression, profound sedation, coma, or even death may occur. In addition, alcohol may affect opioid release from sustained-release formulations.
GENERALLY AVOID: Grapefruit or grapefruit juice may increase the plasma concentrations of opioid analgesics by inhibiting CYP450 3A4-mediated metabolism of these agents, although the interaction has not been studied. In general, the effect of grapefruit juice is concentration-, dose- and preparation-dependent, and can vary widely among brands. Certain preparations of grapefruit juice (e.g., high dose, double strength) have sometimes demonstrated potent inhibition of CYP450 3A4, while other preparations (e.g., low dose, single strength) have typically demonstrated moderate inhibition. Pharmacokinetic interactions involving grapefruit juice are also subject to a high degree of interpatient variability, thus the extent to which a given patient may be affected is difficult to predict.
MANAGEMENT: Patients should not consume alcoholic beverages or use drug products that contain alcohol during treatment with opioid analgesics. Any history of alcohol or illicit drug use should be considered when prescribing an opioid analgesic, and therapy initiated at a lower dosage if necessary. Patients should be closely monitored for signs and symptoms of sedation, respiratory depression, and hypotension. Due to a high degree of interpatient variability with respect to grapefruit juice interactions, patients treated with opioid analgesics should preferably avoid the consumption of grapefruit and grapefruit juice.
References (18)
- (2017) "Product Information. Alfentanil Hydrochloride (alfentanil)." Akorn Inc
- (2024) "Product Information. TraMADol Hydrochloride (traMADol)." Advagen Pharma Ltd
- (2024) "Product Information. Jamp Tramadol (tramadol)." Jamp Pharma Corporation
- (2025) "Product Information. Tramadol (tramadol)." Sigma Pharmaceuticals Plc
- (2024) "Product Information. Tramedo (tRAMadol)." Alphapharm Pty Ltd
- (2022) "Product Information. Alfentanil (alfentanil)." Hameln Pharma Ltd
- (2024) "Product Information. Butorphanol Tartrate (butorphanol)." Apotex Corporation
- (2024) "Product Information. Codeine Sulfate (codeine)." Lannett Company Inc
- (2024) "Product Information. Meperidine Hydrochloride (meperidine)." Genus Lifesciences Inc.
- (2023) "Product Information. Dsuvia (SUFentanil)." AcelRx Pharmaceuticals
- (2024) "Product Information. Dzuveo (sufentanil)." Aguettant Ltd
- (2025) "Product Information. Pethidine (pethidine)." Martindale Pharmaceuticals Ltd
- (2023) "Product Information. Meperidine Hydrochloride (meperidine)." Sandoz Canada Incorporated
- (2024) "Product Information. Pethidine (Juno) (pethidine)." Juno Pharmaceuticals Pty Ltd
- Cherrier MM, Shen DD, Shireman L, et al. (2021) "Elevated customary alcohol consumption attenuates opioid effects." Pharmacol Biochem Behav, 4, p. 1-27
- Fuhr LM, Marok FZ, Fuhr U, Selzer D, Lehr T (2023) "Physiologically based pharmacokinetic modeling of bergamottin and 6,7-dihydroxybergamottin to describe CYP3A4 mediated grapefruit-drug interactions." Clin Pharmacol Ther, 114, p. 470-82
- (2025) "Product Information. TraMADol Hydrochloride ER (traMADol)." Trigen Laboratories Inc
- (2025) "Product Information. Codeine Contin (codeine)." Purdue Pharma
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.